
The traditional "one gene, one protein" paradigm is insufficient to capture the vast phenotypic and physiological complexity of eukaryotes. This review aims to comprehensively elucidate the molecular mechanisms of transcriptomic diversification, namely, alternative splicing, alternative usage of promoter, and alternative polyadenylation, and their profound impacts on cellular homeostasis and human disease. By synthesizing recent breakthroughs in targeted long-read RNA sequencing, single-cell isoform-specific multiomics, and AI-driven 3D structural modeling, we systematically examine how transcript variants are generated and functionally annotated. Our analysis highlights that multiple transcript variants originating from a single genetic locus are not merely redundant copies; rather, subtle sequence alterations dynamically rewire protein-protein interaction networks and dictate precise subcellular localization. The exquisite spatiotemporal regulation of these variants controls critical cell fate decisions and organ development. Consequently, the pathological dysregulation of these processes, frequently termed spliceopathies, acts as a primary driver in severe pathologies, including cancer multidrug resistance, metabolic reprogramming, and neurodegenerative disorders. In conclusion, understanding the eukaryotic proteome requires a fundamental shift from conventional gene-level to isoform-level perspectives. Decoding the complex regulatory syntax of transcript variants paves the way for next-generation precision medicine, highlighting the therapeutic potential of RNA-targeted interventions, such as antisense oligonucleotides and CRISPR-based RNA editing, to correct pathogenic isoforms.
Cardiometabolic disease reflects interdependent dysfunction across adipose tissue, liver, skeletal muscle, vasculature, and heart. p21-activated kinase 4 (PAK4), a group II serine/threonine kinase controlling cytoskeletal organization and development, has emerged as a nutrient-responsive regulator in metabolic tissues. We position PAK4 as a candidate cardiometabolic node rather than a proven master regulator or direct energy sensor. Established mechanisms include suppression of adipocyte lipolysis and browning, hepatocyte NCoR1-PPARα-dependent fattyacid oxidation and ketogenesis, skeletal-muscle AMPKα2-GLUT4 signaling, together with promotion of hepatic stellate-cell activation via YAP phosphorylation at Thr428. These programs could alter the substrate, inflammatory, redox, and endocrine environment encountered by the cardiovascular system. We refine the hepatic ketone deficiency concept into a PAK4-ketone supply-demand mismatch hypothesis: reduced hepatic ketogenesis may limit adaptive ketone availability when myocardial demand rises, though inter-organ causality remains unproven. PAK4 is essential for embryonic cardiac morphogenesis, and limited adult endothelial studies suggest stress-protective roles in ischemic and inflammatory settings, whereas functions in adult cardiomyocytes, fibroblasts, and vascular smooth muscle cells remain largely undefined. An exploratory scan of Gene Expression Omnibus datasets identified recurrent nominal increases in PAK4 mRNA in selected failing or remodeled human myocardium and steatotic liver, but no universal cardiometabolic signature. These findings define a tissue-dependent therapeutic dilemma in which peripheral metabolic benefits of PAK4 inhibition or degradation may coexist with uncharacterized cardiac, isoform, and exposure-related risks. Resolving this paradox will require adult inducible cell-specific models, inter-organ flux studies, cardiac proteomics and phosphoproteomics, and comparison of catalytic inhibitors, degraders, and tissuedirected delivery systems.